Hongli Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hongli Wu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Haipeng He
Department of Epidemiology and Health Statistic, College of Public Health of Hebe University, Baoding City, HeBei Province, China.
1 shared publication - Hui Liu
Department of Epidemiology and Health Statistic, College of Public Health of Hebe University, Baoding City, HeBei Province, China.
1 shared publication - Hui Zhang
Affiliated Hospital of HeBei University, Baoding City, HeBei Province, China.
1 shared publication - Huiling Xue
Affiliated Hospital of HeBei University, Baoding City, HeBei Province, China.
1 shared publication - Huiling Xue
Hebei Univ, Affiliated Hosp, Dept Reprod Med, Baoding 071000, Peoples R China
1 shared publication - Junrong Shi
Affiliated Hospital of HeBei University, Baoding City, HeBei Province, China.
1 shared publication
Latest Publications
- Open Access
- 28 March 2015
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 8 (1) , 19
Relationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification
The purpose of this study is to identify a prospective association between CA125 and tumorigenic ovarian cancer cells, using the new method of orthotopic transplantation (1). After making the surgical ovarian cancer specimen into cell suspension, we separated the tumorigenic cells from the nontumorigenic cancer cells based on cell surface marker (cancer antigen CA125 and lineage markers) expression. We developed a SCID mice model in which the CA125+/ lineage- and CA125-/ lineage- cells were injected into ovarian parenchyma by use of a microinjector. As a measure of effectiveness of tumor-forming, tumor weight, abdominal distension, ascites volume and activity, subcutaneous fat were determined or observed. Immunohistochemistry was done to determine tumor cell markers. We found that the cells of CA125+/ lineage- were able to form new tumors; whereas, an equal quantity of CA125-/lineage- cells failed to form any tumors. The new generated tumor contained additional CA125-/lineage- tumorigenic cells as well as the phenotypically diverse population of nontumorigenic cells. Quantities were judged to be significantly different P < 0.0001. CA125+/ lineage- cells, which may be ovarian cancer stem cells, were the source for tumor recurrence. The strategies designed to target this cell population may lead to more effective therapies.
- 28 March 2015
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 8 (1) , 19
Open AccessRelationship of tumor marker CA125 and ovarian tumor stem cells: preliminary identification
The purpose of this study is to identify a prospective association between CA125 and tumorigenic ovarian cancer cells, using the new method of orthotopic transplantation (1). After making the surgical ovarian cancer specimen into cell suspension, we separated the tumorigenic cells from the nontumorigenic cancer cells based on cell surface marker (cancer antigen CA125 and lineage markers) expression. We developed a SCID mice model in which the CA125+/ lineage- and CA125-/ lineage- cells were injected into ovarian parenchyma by use of a microinjector. As a measure of effectiveness of tumor-forming, tumor weight, abdominal distension, ascites volume and activity, subcutaneous fat were determined or observed. Immunohistochemistry was done to determine tumor cell markers. We found that the cells of CA125+/ lineage- were able to form new tumors; whereas, an equal quantity of CA125-/lineage- cells failed to form any tumors. The new generated tumor contained additional CA125-/lineage- tumorigenic cells as well as the phenotypically diverse population of nontumorigenic cells. Quantities were judged to be significantly different P < 0.0001. CA125+/ lineage- cells, which may be ovarian cancer stem cells, were the source for tumor recurrence. The strategies designed to target this cell population may lead to more effective therapies.